Live Breaking News & Updates on Sperogenix Therapeutics

Stay updated with breaking news from Sperogenix therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating ....

United States , United Kingdom , Switzerland General , Shabir Hasham , Dario Eklund , Andrew Smith , Eva Kalias , Chiesi Farmaceutici , America To Catalyst Pharmaceuticals Inc , Life Science Alliance , National Institute For Health , Santhera Pharmaceuticals Holding , Catalyst Pharmaceuticals Inc , Exchange Regulation Ltd , Regulatory Agency , Santhera Pharmaceuticals Holding Ltd , Drug Administration , Chiesi Group , European Medicines Agency , European Union Summary Of Product Characteristics , Exchange Regulation , Catalyst Pharmaceuticals , Head Investor Relations Communications , China National Medical Products Administration , Santhera Pharmaceuticals , Announces Preliminary Unaudited ,

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , Switzerland General , United States , Dennis Riedl , Eva Kalias , Dario Eklund , Shabir Hasham , Chiesi Farmaceutici , Andrew Smith , Santhera Pharmaceuticals , China National Medical Products Administration , Catalyst Pharmaceuticals , Head Investor Relations Communications , Exchange Regulation , European Medicines Agency , European Union Summary Of Product Characteristics , Chiesi Group , Santhera Pharmaceuticals Holding Ltd , Exchange Regulation Ltd , Catalyst Pharmaceuticals Inc , Santhera Pharmaceuticals Holding , National Institute For Health , Announces Preliminary Unaudited , Provides Corporate Update Ahead , Full Report Publication , North America ,

Santhera's vamorolone NDA receives priority review in China

Santhera has reported that the China NMPA granted priority review for a new drug application (NDA) for vamorolone for Duchenne muscular dystrophy. ....

United Kingdom , Sperogenix Therapeutics , Drug Evaluation ,

Santhera Pharmaceuticals Holding AG: Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA

Santhera Pharmaceuticals Holding AG: Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland General , North Lanarkshire , United Kingdom , Eva Kalias , Dennis Riedl , Breakthrough Therapy Program , Head Investor Relations Communications , China National Medical Products Administration , Santhera Pharmaceuticals , European Union , Santhera Pharmaceuticals Holding , Sperogenix Therapeutics , Drug Evaluation , Lilly Asia Ventures , Morningside Ventures , Head Investor Relations ,

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA -March 27, 2024 at 02:01 am EDT

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA -March 27, 2024 at 02:01 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Switzerland General , United Kingdom , United States , North Lanarkshire , Eva Kalias , America To Catalyst Pharmaceuticals Inc , Santhera Pharmaceuticals Holding , Drug Administration , Regulatory Agency , Breakthrough Therapy Program , Santhera Pharmaceuticals , European Union Summary Of Product Characteristics , China National Medical Products Administration , Globenewswire Inc , European Medicines Agency , Life Science Alliance , National Medical Products Administration , Sperogenix Therapeutics , Drug Evaluation , Prescribing Information , Product Characteristics , Natl Acad Sci United States , Asia Ventures , Medicines Agency , Catalyst Pharmaceuticals , Head Investor Relations ,